Latest Market Expansion News

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.

AI-Media Technologies marked FY25 as a pivotal year, transitioning to a technology-led business with 63% of revenue from tech products and launching LEXI Voice. The company expanded its global footprint to 36 countries and set ambitious targets for FY29.

AI-Media Technologies has accelerated its transformation into a technology-led business, reporting a 19% increase in technology revenue and launching its AI-powered LEXI Voice product in FY25.

Ai-Media Technologies reported a 2.1% revenue decline to $64.86 million in FY25, driven by a strategic shift to technology sales and a 25% drop in services revenue. Despite a higher net loss, underlying EBITDA rose 11%, reflecting progress in its SaaS transformation and global expansion.

RocketDNA Ltd reported a slight revenue decline and increased losses in H1 2025 but marked significant progress in drone technology deployments and operational certifications.

Shriro Holdings reported a 5.5% rise in EBITDA for FY25 despite a 13.6% revenue dip, driven by strategic shifts including a new US distributor and innovative BBQ product launches.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.